5VB.F Vaccibody AS

Healthcare Biotechnology Frankfurt Exchange
0.2360 EUR
Close of Nov 11, 2026
0.1395 0.4460
Market cap
EUR 92.4M
P/E
-
P/B
1.32x
ROE
-28.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 5VB.F undervalued?

Graham number

The Graham number of Vaccibody AS cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Vaccibody AS fundamental analysis

No fundamental analysis for Vaccibody AS yet.

Vaccibody AS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Vaccibody AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in…

Full company profile